Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: Results of the MEDCOR trial

Autor: Antoine Guedes, Arnold G. Herman, Bruno Pirenne, Emanuele Barbato, Luc Janssens, Edouard Benit, Patrick Chenu, William Wijns, François Cardinal, Etienne Hoffer, Luc Missault, Jacques Lalmand, Steven Vercauteren
Přispěvatelé: Barbato, Emanuele, Herman, Arnold, Benit, Edouard, Janssens, Luc, Lalmand, Jacque, Hoffer, Etienne, Chenu, Patrick, Guédès, Antoine, Missault, Luc, Pirenne, Bruno, Cardinal, Françoi, Vercauteren, Steven, Wijns, William
Rok vydání: 2015
Předmět:
Male
Stable angina
Time Factors
Vasodilator Agents
medicine.medical_treatment
Coronary Artery Disease
law.invention
chemistry.chemical_compound
Belgium
Randomized controlled trial
law
Vasodilator Agent
Endothelial dysfunction
Middle Aged
Intercellular Adhesion Molecule-1
Combined Modality Therapy
Reactive hyperemia-peripheral arterial tonometry
Vasodilation
Treatment Outcome
Atherosclerosi
Cardiology
Female
Cardiology and Cardiovascular Medicine
Human
Nitric oxide donor
medicine.medical_specialty
Molsidomine
Time Factor
Manometry
Placebo
Nitric oxide
Percutaneous Coronary Intervention
Double-Blind Method
Internal medicine
medicine
Humans
Nitric Oxide Donors
In patient
Angina
Stable
Aged
Peroxidase
business.industry
Percutaneous coronary intervention
Biomarker
medicine.disease
chemistry
Endothelium
Vascular
business
Biomarkers
Zdroj: Atherosclerosis. 240:351-354
ISSN: 0021-9150
Popis: The MEDCOR trial is a double-blind, randomized study aiming at demonstrating the superiority of molsidomine (direct NO donor) over placebo, used as add-on treatments, on improving endothelial function (EF) after 12 months, in stable angina patients undergoing percutaneous coronary intervention.EF was assessed by peripheral vasodilator response (i.e. Endoscore) using arterial tonometry and by several biomarkers, in terms of changes versus baseline after a one-year treatment.The change in Endoscore was +75 ± 130% in placebo group and +39 ± 145% in molsidomine group (p = 0.143). There was a decrease in sICAM-1 with molsidomine (-6%) and an increase with placebo (+6%). The MPO activity/antigen ratio slightly increased with placebo (+9%) and strongly decreased with molsidomine (-42%) (p = 0.020).The MEDCOR trial was not able to demonstrate significant differences between molsidomine and placebo for all parameters, except the MPO activity/antigen ratio which significantly decreased with molsidomine (p = 0.020 versus placebo).
Databáze: OpenAIRE
Externí odkaz: